乳腺癌患者化疗前后血清IGFⅠ、CA153、VEGF水平检测的临床意义

Clinical Significance of Determination of Changes on Serum IGFⅠ,CA153,VEGF Levels after Chemothe Rapy in patients with Breast Cancer

目的:探讨乳腺癌患者化疗前后血清IGFⅠ,CA153,VEGF水平的变化及其临床意义。方法:应用放射免疫分析结合酶联法对33例乳腺癌患者进行了血清IGFⅠ,CA153,VEGF测定,并与35例正常健康人作比较。结果:乳腺癌患者在化疗前血清IGFⅠ、CA153、VEGF水平均显著地高于正常人组(P<0.0l),化疗后一年复发组又明显高于未复发组(P<0.05)。结论:检测乳腺癌患者化疗前后血清IGFⅠ,CA153,VEGF水平的变化与乳腺癌的病情和预后密切相关,具有重要的临床价值。

Objective To investigate the patients with breast cancer before and after Chemotherapy of serum IGF I, CA153 and VEGF and their clinical significances. Method Serum CA153 （with RIA） ,serum IGF I and VEGF（with ELISA） levels were determined in 33 patients with breast cancer both before and after chemotherapy as well as in 35 normal healthy controls. Results In patients with breast cancer before chemotherapy of serum IGF, CA153, VEGF levels were significantly higher than those in normal group （P 〈 0. 01）, one year after chemotherapy recurrence group was significantly higher than non recurrent group （ P 〈 0.05 ）. Conclusion The detection of breast cancer before and after chemotherapy in patients with serum IGF I, CA153, VEGF levels are closely related to the severity and prognosis of breast cancer, they have important clinical value.